FDAAA International Network (FDAAA IN) Visits with China FDA Officials

On May 8, 2014, a FDAAA IN delegation was invited to meet with Dr. YUAN Lin, Director General of the CFDA Department of International Cooperation. Dr. YUAN and FDAAA discussed the importance of international exchange and regulatory science training within CFDA. Dr. YUAN attended the May 11 Pre-conference workshop on GxP FDAAA ran at the DIA China in Shanghai. After the workshop he was very enthusiastic about the role FDAAA can play in China. The below photo is taken May 8th outside the CFDA headquarters in Beijing.

Left to Right: Chi-wan CHEN (FDAAA IN Planning Group Member and Pfizer), Mark Goldberger (FDAAA and AbbVie), Florence Houn (FDAAA IN Co-chair and Celgene), YUAN Lin (Head of CFDA International Cooperation), Zili Li (FDAAA IN Co-Chair and Bill & Melinda Gates Foundation), and John Gong (FDAAA and Bei-gene)

Also on May 8th, the FDAAA was invited to meet with the acting director for CFDA’s Center for Drug Evaluation (CDE), Dr. XU Jiaqi and Dr. WANG Qingli, Head of Pharmacology-Toxicology Review Office. Dr. XU thanked FDAAA for its many years of regulatory science exchange. He discussed the need for efficiency in the review process. He was open to hearing experiences that the US FDA has implemented over the years to improve review efficiency that may be relevant to the China situation.

Left to Right: Mark Goldberger, Chi-wan Chen, Florence Houn, XU Jiaqi (CFDA CDE Acting Director), Zili Li, WANG Qingli (Head of Pharm-Tox Review Office) and John Gong